Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review

References

• Ibrahim H, Saad A, Abdo A, et al. Mining association patterns of drug-interactions using post marketing FDA’s spontaneous reporting data. J Biomed Informat. 2016;60:294–308. doi: 10.1016/j.jbi.2016.02.009
   PubMed Web of Science ®Google Scholar
• Zhang T, Leng J, Liu Y. Deep learning for drug–drug interaction extraction from the literature: a review. Brief Bioinform. 2020;21(5):1609–1627. doi: 10.1093/bib/bbz087
   PubMed Web of Science ®Google Scholar
• Spina E, Barbieri MA, Cicala G, et al. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals (Basel). 2020;13(12):439. doi: 10.3390/ph13120439
   PubMedGoogle Scholar
• Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J Pharmacol Exp Ther. 2019;370(3):570–580. doi: 10.1124/jpet.119.257113
   PubMed Web of Science ®Google Scholar
• Strandell J, Caster O, Bate A, et al. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf. 2011;34(3):253–266. doi: 10.2165/11586990-000000000-00000
   PubMed Web of Science ®Google Scholar
• Palleria C, Roberti R, Iannone LF, et al. Clinically relevant drug interactions between statins and antidepressants. J Clin Pharm Ther. 2020;45(2):227–239. doi: 10.1111/jcpt.13058
   PubMed Web of Science ®Google Scholar
• Huang J, Niu C, Green CD, et al. Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network. PLOS Comput Biol. 2013;9(3):e1002998. doi: 10.1371/journal.pcbi.1002998
   PubMed Web of Science ®Google Scholar
• Spina E, Barbieri MA, Cicala G, et al. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert Opin Drug Metab Toxicol. 2020;16(1):31–44. doi: 10.1080/17425255.2020.1700952
   PubMed Web of Science ®Google Scholar
• Wang X, Li L, Wang L, et al. Propensity score‐adjusted three‐component mixture model for drug‐drug interaction data mining in FDA Adverse Event Reporting System. Stat Med. 2020;39(7):996–1010. doi: 10.1002/sim.8457
   PubMed Web of Science ®Google Scholar
• Carnovale C, Mosini G, Gringeri M, et al. Interaction between paracetamol and lamotrigine: new insights from the FDA Adverse Event Reporting System (FAERS) database. Eur J Clin Pharmacol. 2019;75(9):1323–1325. doi: 10.1007/s00228-019-02691-4
   PubMed Web of Science ®Google Scholar
• Cutroneo PM, Sartori D, Tuccori M, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024;3:1323057. doi: 10.3389/fdsfr.2023.1323057
   Google Scholar
• Good pharmacovigilance practices | European Medicines Agency [Internet]. [cited 2024 Feb 28]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices.
   Google Scholar
• Vignolini G, Sessa F, Greco I, et al. Intraoperative assessment of ureteral and graft reperfusion during robotic kidney transplantation with indocyanine green fluorescence videography. Minerva Urol Nefrol. 2019;71(1):79–84. doi: 10.23736/S0393-2249.18.03278-2
   PubMed Web of Science ®Google Scholar
• Hagengaard L, Søgaard P, Espersen M, et al. Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):137–144. doi: 10.1093/ehjcvp/pvz024
   PubMed Web of Science ®Google Scholar
• Sessa M, Rossi C, Mascolo A, et al. Suspected adverse reactions to contrast media in Campania Region (Italy): Results from 14 years of post-marketing surveillance. Expert Opin Drug Saf. 2015;14(9):1341–1351. doi: 10.1517/14740338.2015.1067301
   PubMed Web of Science ®Google Scholar
• Sullivan T, Nord M, Domalik D, et al. A structured methodology to assess safety signal strength and inform causality assessment. Pharm Med. 2022;36(4):215–222. doi: 10.1007/s40290-022-00436-w
   PubMed Web of Science ®Google Scholar
• Shang N, Xu H, Rindflesch TC, et al. Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Informat. 2014;52:293–310. doi: 10.1016/j.jbi.2014.07.011
   PubMed Web of Science ®Google Scholar
• Kahn MG, Callahan TJ, Barnard J, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC). 2016;4, p. 1244.
   Google Scholar
• Noguchi Y, Yoshizawa S, Aoyama K, et al. Verification of the “upward variation in the reporting odds ratio scores” to detect the signals of drug–drug interactions. Pharmaceutics. 2021;13(10):1531. doi: 10.3390/pharmaceutics13101531
   PubMed Web of Science ®Google Scholar
• Strandell J, Caster O, Hopstadius J, et al. The development and evaluation of triage algorithms for early discovery of adverse drug interactions. Drug Saf. 2013;36(5):371–388. doi: 10.1007/s40264-013-0053-7
   PubMed Web of Science ®Google Scholar
• Vilar S, Friedman C, Hripcsak G. Detection of drug–drug interactions through data mining studies using clinical sources, scientific literature and social media. Brief Bioinform. 2018;19(5):863–877. doi: 10.1093/bib/bbx010
   PubMed Web of Science ®Google Scholar
• Landmark CJ, Johannessen SI. Safety aspects of antiepileptic drugs—focus on pharmacovigilance. Pharmacoepidemiol Drug Saf. 2012;21(1):11–20. doi: 10.1002/pds.2269
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhang Y, Deng Y, et al. A comprehensive review of computational methods for drug-drug interaction detection. IEEE/ACM Trans Comput Biol And Bioinf. 2022;19(4):1968–1985. doi: 10.1109/TCBB.2021.3081268
   PubMed Web of Science ®Google Scholar
• Lee CY, Chen Y-P. Prediction of drug adverse events using deep learning in pharmaceutical discovery. Brief Bioinform. 2021;22(2):1884–1901. doi: 10.1093/bib/bbaa040
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Tachi T, Teramachi H. Review of statistical methodologies for detecting drug–drug interactions using spontaneous reporting systems. Front Pharmacol. 2019;10:1319. doi: 10.3389/fphar.2019.01319
   PubMed Web of Science ®Google Scholar
• Chapter 11: Scoping reviews - JBI Manual for Evidence Synthesis - JBI Global Wiki [Internet]. [cited 2023 Aug 13]. Available from: https://jbi-global-wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews.
   Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. doi: 10.1080/1364557032000119616
   Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467–473. doi: 10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing [Internet]. Vienna (Austria): The R Foundation for Statistical Computing; 2021. Available from: https://www.R-project.org/.
   Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136/bmj.n160
   PubMed Web of Science ®Google Scholar
• Abe J, Umetsu R, Uranishi H, et al. Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. PLOS ONE. 2017;12(12):e0190102. doi: 10.1371/journal.pone.0190102
   PubMed Web of Science ®Google Scholar
• Almenoff JS, DuMouchel W, Kindman LA, et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf. 2003;12(6):517–521. doi: 10.1002/pds.885
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Karas RH. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. Am J Cardiol. 2004;93(11):1417–1418. doi: 10.1016/j.amjcard.2004.02.045
   PubMed Web of Science ®Google Scholar
• Antonazzo IC, Poluzzi E, Forcesi E, et al. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system. Acta Diabetol. 2020;57(1):71–80. doi: 10.1007/s00592-019-01378-7
   PubMed Web of Science ®Google Scholar
• Cai R, Liu M, Hu Y, et al. Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports. Artif Intell Med. 2017;76:7–15. doi: 10.1016/j.artmed.2017.01.004
   PubMed Web of Science ®Google Scholar
• Chasioti D, Yao X, Zhang P, et al. Mining directional drug interaction effects on myopathy using the FAERS database. IEEE J Biomed Health Inform. 2019;23(5):2156–2163. doi: 10.1109/JBHI.2018.2874533
   PubMed Web of Science ®Google Scholar
• Chen J, Wu G, Michelson A, et al. Mining reported adverse events induced by potential opioid-drug interactions. JAMIA Open. 2020;3(1):104–112. doi: 10.1093/jamiaopen/ooz073
   PubMedGoogle Scholar
• Chrétien B, Nguyen S, Dolladille C, et al. Association between road traffic accidents and drugs belonging to the antiseizure medications class: A pharmacovigilance analysis in VigiBase. Brit J Clin Pharma. 2023;89(1):222–231. doi: 10.1111/bcp.15481
   PubMed Web of Science ®Google Scholar
• Cohen IV, Makunts T, Abagyan R, et al. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep. 2021;11(1):5997. doi: 10.1038/s41598-021-85389-x
   PubMedGoogle Scholar
• Contejean A, Tisseyre M, Canouï E, et al. Combination of vancomycin plus piperacillin and risk of acute kidney injury: a worldwide pharmacovigilance database analysis. J Antimicrob Chemother. 2021;76(5):1311–1314. doi: 10.1093/jac/dkab003
   PubMed Web of Science ®Google Scholar
• Fahim SM, Mishuk AU, Cheng N, et al. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2019;18(2):145–152. doi: 10.1080/14740338.2019.1562546
   PubMed Web of Science ®Google Scholar
• Fan Q, Hu Y, Yang C, et al. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. Int Immunopharmacol. 2019;76:105866. doi: 10.1016/j.intimp.2019.105866
   PubMed Web of Science ®Google Scholar
• Fernandez S, Lenoir C, Samer C, et al. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Pharmacol Res Perspect. 2020;8(5):8. doi: 10.1002/prp2.647
   Web of Science ®Google Scholar
• Fernandez S, Lenoir C, Samer CF, et al. Drug-drug interactions leading to adverse drug reactions with Rivaroxaban: a systematic review of the literature and analysis of VigiBase. JPM. 2021;11(4):250. doi: 10.3390/jpm11040250
   Google Scholar
• Gandhi PK, Gentry WM, Bottorff MB. Dabigatran–dronedarone interaction in a spontaneous reporting system. J Am Pharm Assoc. 2013;53(4):414–419. doi: 10.1331/JAPhA.2013.12218
   Google Scholar
• Gómez-Lumbreras A, Boyce RD, Villa-Zapata L, et al. Drugs that interact with colchicine via inhibition of cytochrome P450 3A4 and P-Glycoprotein: a signal detection analysis using a database of spontaneously reported adverse events (FAERS). Ann Pharmacother. 2023;57(10):1137–1146. doi: 10.1177/10600280221148031
   PubMed Web of Science ®Google Scholar
• Gosho M, Maruo K, Tada K, et al. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. Eur J Clin Pharmacol. 2017;73(6):779–786. doi: 10.1007/s00228-017-2233-3
   PubMed Web of Science ®Google Scholar
• Gosho M. Risk of hypoglycemia after concomitant use of antidiabetic, antihypertensive, and antihyperlipidemic medications: a database study. J Clin Pharmacol. 2018;58(10):1324–1331. doi: 10.1002/jcph.1147
   PubMed Web of Science ®Google Scholar
• Gosho M. Rhabdomyolysis risk from the use of two‐drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis. Fundam Clin Pharmacol. 2019;33(3):339–346. doi: 10.1111/fcp.12435
   PubMed Web of Science ®Google Scholar
• Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinf. 2010;11(S9):S7. doi: 10.1186/1471-2105-11-S9-S7
   PubMedGoogle Scholar
• Hauben M, Reich L, Gerrits CM, et al. Detection of Spironolactone-associated hyperkalaemia following the randomized aldactone evaluation study (RALES). Drug Saf. 2007;30(12):1143–1149. doi: 10.2165/00002018-200730120-00006
   PubMed Web of Science ®Google Scholar
• Hauben M, Hung EY. A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. J Clin Pharmacol. 2013;53(7):762–772. doi: 10.1002/jcph.84
   PubMed Web of Science ®Google Scholar
• Hult S, Sartori D, Bergvall T, et al. A feasibility study of drug–drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020;43(8):775–785. doi: 10.1007/s40264-020-00939-y
   PubMed Web of Science ®Google Scholar
• Ikemura K, Hiramatsu S, Shinogi Y, et al. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Sci Rep. 2019;9(1):20359. doi: 10.1038/s41598-019-56900-2
   PubMedGoogle Scholar
• Inaba I, Kondo Y, Iwasaki S, et al. Risk evaluation for acute kidney injury induced by the concomitant use of valacyclovir, analgesics, and renin–angiotensin system inhibitors: the detection of signals of drug–drug interactions. Front Pharmacol. 2019;10:874. doi: 10.3389/fphar.2019.00874
   PubMed Web of Science ®Google Scholar
• Jeong E, Nelson SD, Su Y, et al. Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front Pharmacol. 2022;13:938552. doi: 10.3389/fphar.2022.938552
   PubMed Web of Science ®Google Scholar
• Jeong E, Person AK, Stollings JL, et al. Detecting drug-drug interactions in COVID-19 patients. Stud Health Technol Inform. 2022;290:330–334.
   PubMedGoogle Scholar
• Kamdar MR, Tech M, Musen MA Mechanism-based Pharmacovigilance over the life sciences linked open data cloud. AMIA Annual Symposium Proceedings American Medical Informatics Association. 2017;2017:p. 1014–1023.
   Google Scholar
• Labat V, Arnaud M, Miremont-Salamé G, et al. Risk of myopathy associated with DPP-4 inhibitors in combination with statins: a disproportionality analysis using data from the WHO and French Spontaneous Reporting Databases. Diabetes Care. 2017;40(3):e27–e29. doi: 10.2337/dc16-1822
   PubMed Web of Science ®Google Scholar
• Li H, Deng J, Yue Z, et al. Detecting drug–herbal interaction using a spontaneous reporting system database: an example with benzylpenicillin and qingkailing injection. Eur J Clin Pharmacol. 2015;71(9):1139–1145. doi: 10.1007/s00228-015-1898-8
   PubMed Web of Science ®Google Scholar
• Li Y, Zhan P, Sun Z, et al. Data-driven prediction of beneficial drug combinations in spontaneous reporting systems. AMIA Annu Symp Proc. 2016;2016:808–817.
   PubMedGoogle Scholar
• Lin S-F, Xiao K-T, Huang Y-T, et al. Analysis of adverse drug reactions using drug and drug target interactions and graph-based methods. Artif Intell Med. 2010;48(2–3):161–166. doi: 10.1016/j.artmed.2009.11.002
   PubMed Web of Science ®Google Scholar
• Liu N, Chen C-B, Kumara S. Semi-supervised learning algorithm for identifying high-priority drug–drug interactions through adverse event reports. IEEE J Biomed Health Inform. 2020;24(1):57–68. doi: 10.1109/JBHI.2019.2932740
   PubMed Web of Science ®Google Scholar
• French Association of Regional Pharmacovigilance Centers, Maschino F, Hurault-Delarue C, et al. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol. 2012;68(11):1557–1560.
   PubMed Web of Science ®Google Scholar
• Matsuo J, Yamaori S. Detecting drug‐drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system. Clinical Pharmacy Therapeu. 2022;47(1):70–80. doi: 10.1111/jcpt.13539
   Google Scholar
• Matsuo J, Yamaori S, Murai K, et al. Detecting coadministered drugs that affect the incidence of long QT syndrome associated with fluoroquinolone antibiotics using a spontaneous reporting system. J Pharmacovigil. 2020;8:1–8.
   Google Scholar
• Meng L, Huang J, Qiu F, et al. Peripheral neuropathy during concomitant administration of proteasome inhibitors and factor Xa inhibitors: identifying the likelihood of drug-drug interactions. Front Pharmacol. 2022;13:757415. doi: 10.3389/fphar.2022.757415
   PubMed Web of Science ®Google Scholar
• Montastruc F, Benevent J, Rousseau V, et al. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase ®. Fundam Clin Pharmacol. 2019;33(1):108–112. doi: 10.1111/fcp.12406
   PubMedGoogle Scholar
• Montastruc J-L, Toutain P-L. A new drug–drug interaction between hydroxychloroquine and metformin? A signal detection study. Drug Saf. 2020;43(7):657–660. doi: 10.1007/s40264-020-00955-y
   PubMed Web of Science ®Google Scholar
• Nishiuchi S, Yagi K, Saito H, et al. Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis. Eur J Pharmacol. 2022;928:175083. doi: 10.1016/j.ejphar.2022.175083
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Ueno A, Otsubo M, et al. A new search method using association rule mining for drug-drug interaction based on spontaneous report system. Front Pharmacol. 2018;9:197. doi: 10.3389/fphar.2018.00197
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Tachi T, Teramachi H. Subset analysis for screening drug–drug interaction signal using pharmacovigilance database. Pharmaceutics. 2020;12(8):762. doi: 10.3390/pharmaceutics12080762
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Tachi T, Teramachi H. Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems. Pharm Res. 2020;37(5):86. doi: 10.1007/s11095-020-02801-3
   PubMed Web of Science ®Google Scholar
• Norén GN, Sundberg R, Bate A, et al. A statistical methodology for drug–drug interaction surveillance. Stat Med. 2008;27(16):3057–3070. doi: 10.1002/sim.3247
   PubMed Web of Science ®Google Scholar
• Okunaka M, Kano D, Matsui R, et al. Evaluation of the expression profile of irinotecan-induced diarrhea in patients with colorectal cancer. Pharmaceuticals (Basel). 2021;14(4):377. doi: 10.3390/ph14040377
   PubMedGoogle Scholar
• Pariente A, Sanctussy D-R, Miremont-Salamé G, et al. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs. 2010;24(1):55–63. doi: 10.2165/11530300-000000000-00000
   PubMed Web of Science ®Google Scholar
• Qian Y, Ye X, Du W, et al. A computerized system for detecting signals due to drug–drug interactions in spontaneous reporting systems. Brit J Clin Pharma. 2010;69(1):67–73. doi: 10.1111/j.1365-2125.2009.03557.x
   PubMed Web of Science ®Google Scholar
• Racz R, Soldatos TG, Jackson D, et al. Association between serotonin syndrome and second-generation antipsychotics via pharmacological target-adverse event analysis: association between serotonin syndrome and second generation antipsychotics via pharmacological target-adverse event analysis. Clinical Translational Sci. 2018;11(3):322–329. doi: 10.1111/cts.12543
   PubMed Web of Science ®Google Scholar
• Sainz-Gil M, Merino Kolly N, Velasco-González V, et al. Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions. Expert Opin Drug Saf. 2023;22(1):71–79. doi: 10.1080/14740338.2022.2078303
   PubMed Web of Science ®Google Scholar
• Sarayani A, Cicali B, Henriksen CH, et al. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Administrative Pharm. 2021;17(2):483–486. doi: 10.1016/j.sapharm.2020.04.016
   PubMed Web of Science ®Google Scholar
• Sato K, Mano T, Iwata A, et al. Safety of memantine in combination with potentially interactive drugs in the real world: a pharmacovigilance study using the Japanese adverse drug event report (JADER) database. JAD. 2021;82(3):1333–1344. doi: 10.3233/JAD-210524
   Google Scholar
• Shibata Y, Tamemoto Y, Singh SP, et al. Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. Drug Metabol Pharmacokinetics. 2021;39:100396. doi: 10.1016/j.dmpk.2021.100396
   PubMed Web of Science ®Google Scholar
• Souza-Peres JV, Flores K, Umloff B, et al. Everyday evaluation of herb/dietary supplement–drug interaction: a pilot study. Medicines. 2023;10(3):20. doi: 10.3390/medicines10030020
   Google Scholar
• Strandell J, Bate A, Hägg S, et al. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Brit J Clin Pharma. 2009;68(3):427–434. doi: 10.1111/j.1365-2125.2009.03473.x
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yuen NA, Ilic K, et al. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. Regul Toxicol Pharmacol. 2015;72(3):481–490. doi: 10.1016/j.yrtph.2015.05.004
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Suzuki H, Umetsu R, et al. Analysis of the interaction between clopidogrel, aspirin, and proton pump inhibitors using the FDA adverse event reporting system database. Biol Pharm Bull. 2015;38(5):680–686. doi: 10.1248/bpb.b14-00191
   PubMed Web of Science ®Google Scholar
• Tada K, Gosho M. Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium‐dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: An observational study. Fundamental Clinical Pharma. 2022;36(6):1106–1114. doi: 10.1111/fcp.12792
   PubMed Web of Science ®Google Scholar
• Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc. 2012;19(1):79–85. doi: 10.1136/amiajnl-2011-000214
   PubMed Web of Science ®Google Scholar
• Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug–drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64(4):489–495. doi: 10.1111/j.1365-2125.2007.02900.x
   PubMed Web of Science ®Google Scholar
• Tod M, Rodier T, Auffret M. Quantitative prediction of adverse event probability due to pharmacokinetic interactions. Drug Saf. 2022;45(7):755–764. doi: 10.1007/s40264-022-01190-3
   PubMed Web of Science ®Google Scholar
• Uno T, Wada K, Hosomi K, et al. Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study. Eur J Clin Pharmacol. 2020;76(1):117–125. doi: 10.1007/s00228-019-02770-6
   PubMed Web of Science ®Google Scholar
• Van Puijenbroek EP, Egberts ACG, Meyboom RHB, et al. Signalling possible drug–drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol. 1999;47(6):689–693. doi: 10.1046/j.1365-2125.1999.00957.x
   PubMed Web of Science ®Google Scholar
• Van Puijenbroek EP, Egberts ACG, Heerdink ER, et al. Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2000;56(9–10):733–738. doi: 10.1007/s002280000215
   PubMed Web of Science ®Google Scholar
• Wang L, Pan W, Wang Q, et al. A modified skip-gram algorithm for extracting drug-drug interactions from AERS reports. Comput Math Meth Med. 2020;2020:1–9. doi: 10.1155/2020/1747413
   Web of Science ®Google Scholar
• Wang L, Shendre A, Chiang C-W, et al. A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach. Brit J Clin Pharma. 2022;88(4):1471–1481. doi: 10.1111/bcp.14762
   PubMed Web of Science ®Google Scholar
• Wang F, Zhou B, Sun H, et al. Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2023;14:1170039. doi: 10.3389/fphar.2023.1170039
   PubMed Web of Science ®Google Scholar
• Xu D, Ham AG, Tivis RD, et al. MSBIS: A multi-step biomedical informatics screening approach for identifying medications that mitigate the risks of metoclopramide-induced tardive dyskinesia. EBioMedicine. 2017;26:132–137. doi: 10.1016/j.ebiom.2017.11.015
   PubMed Web of Science ®Google Scholar
• Yamada T, Mitsuboshi S, Suzuki K, et al. Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database. Basic Clin Pharmacol Toxicol. 2021;129(3):268–272. doi: 10.1111/bcpt.13618
   PubMed Web of Science ®Google Scholar
• Yao X, Tsang T, Sun Q, et al. Mining and visualizing high-order directional drug interaction effects using the FAERS database. BMC Med Inform Decis Mak. 2020;20:50. doi: 10.1186/s12911-020-1053-z
   PubMed Web of Science ®Google Scholar
• Yagi K, Mitstui M, Zamami Y, et al. Investigation of drugs affecting hypertension in bevacizumab‐treated patients and examination of the impact on the therapeutic effect. Cancer Med. 2021;10(1):164–172. doi: 10.1002/cam4.3587
   PubMed Web of Science ®Google Scholar
• Yonezawa R, Sunaga T. Signal of safety due to adverse drug reactions induced by tacrolimus with or without azithromycin. Trans Infect Dis. 2022;24(3):e13833. doi: 10.1111/tid.13833
   PubMed Web of Science ®Google Scholar
• Yue Z, Shi J, Jiang P, et al. Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system: valacyclovir-loxoprofen interaction. Pharmacoepidemiol Drug Saf. 2014;23(11):1154–1159. doi: 10.1002/pds.3626
   PubMed Web of Science ®Google Scholar
• Yue Z, Shi J, Li H, et al. Association between Concomitant Use of Acyclovir or Valacyclovir with NSAIDs and an increased risk of acute kidney injury: data mining of FDA adverse event reporting system. Biol Pharm Bull. 2018;41(2):158–162. doi: 10.1248/bpb.b17-00547
   PubMed Web of Science ®Google Scholar
• Villa-Zapata L, Gómez-Lumbreras A, Horn J, et al. A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug Saf. 2022;45(8):863–871. doi: 10.1007/s40264-022-01200-4
   PubMed Web of Science ®Google Scholar
• Zhan C, Roughead E, Liu L, et al. Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data. J Biomed Informat. 2020;112:103603. doi: 10.1016/j.jbi.2020.103603
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang F, Hu J, et al. Label propagation prediction of drug-drug interactions based on clinical side effects. Sci Rep. 2015;5(1):12339. doi: 10.1038/srep12339
   PubMedGoogle Scholar
• Alkabbani W, Pelletier R, Beazely MA, et al. Drug–drug interaction of the sodium glucose co-transporter 2 inhibitors with statins and myopathy: a disproportionality analysis using adverse events reporting data. Drug Saf. 2022;45(3):287–295. doi: 10.1007/s40264-022-01166-3
   PubMed Web of Science ®Google Scholar
• Bandekar MS, Anwikar SR, Kshirsagar NA. Quality check of spontaneous adverse drug reaction reporting forms of different countries. Pharmacoepidemiol Drug Saf. 2010;19(11):1181–1185. doi: 10.1002/pds.2004
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Ikesue H, Satake R, et al. Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database. Drugs Real World Outcomes. 2022;9(4):659–665. doi: 10.1007/s40801-022-00324-4
   PubMedGoogle Scholar
• Mazhar F, Battini V, Gringeri M, et al. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin Biol Ther. 2021;21(9):1281–1290. doi: 10.1080/14712598.2021.1948529
   PubMed Web of Science ®Google Scholar
• Kara V, Powell G, Mahaux O, et al. Finding needles in the haystack: clinical utility score for prioritisation (cusp), an automated approach for identifying spontaneous reports with the highest clinical utility. Drug Saf. 2023;46(9):847–855. doi: 10.1007/s40264-023-01327-y
   PubMed Web of Science ®Google Scholar
• Muñoz MA, Dal Pan GJ, Wei Y-J-J, et al. Towards automating adverse event review: a prediction model for case report utility. Drug Saf. 2020;43(4):329–338. doi: 10.1007/s40264-019-00897-0
   PubMed Web of Science ®Google Scholar